Login to Your Account

Financings Roundup

Pulmatrix Hastens COPD Trials Via $14M Series B1 Financing

By Jennifer Boggs

Tuesday, August 16, 2011
Pulmatrix Inc. topped off its 2009 $30 million Series B with another $14 million to accelerate development of PUR118, its lead iCALM candidate, through Phase IIa studies in chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription